Disease foundations are advocates, funders, partners
This article was originally published in Scrip
Executive Summary
Companies with preclinical compounds might not think of institutions with limited resources as a first choice for early stage funding, but during a time when financing is hard to come by, disease foundations may be realistic drug development partners.